The UK and US have agreed to a major trade deal focusing on pharmaceuticals, which involves scrapping US tariffs on British medicines for at least three years.
Thank you for reading this post, don't forget to subscribe!Key Provisions
- Zero Tariffs for the UK: The US will apply a zero percent import tariff on British-made pharmaceuticals, ingredients, and medical technology.
- Increased NHS Spending: In exchange, the UK pledged to boost NHS spending on new and effective medicines by roughly 25 percent. This significant investment is expected to help UK regulators approve drugs—especially potential breakthroughs in cancer and rare diseases—that previously failed cost-effectiveness tests.
- Investment Commitments: British drug companies have also committed to expand investment and create jobs in the US.
Impact
- The deal aims to speed up patient access to cutting-edge care in the UK.
- It is intended to revive confidence in the UK life sciences sector and attract global investment, which had recently slowed down.
- The pact is part of a broader effort by President Donald Trump and Prime Minister Keir Starmer to reset overall trade ties, which includes cutting US import taxes on British cars, steel, and aluminum in exchange for the UK opening its market to US goods like beef and ethanol.
